A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
Phase 1
217
about 4 years
18+
8 sites in CA, CT, FL +4
What this study is about
This trial is testing the safety and dosing of BGB-26808 alone or with tislelizumab in people with advanced solid tumors. The goal is to determine the best dose for BGB-26808.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take BGB-26808
- 2.Take Chemotherapy
- 3.Take Tislelizumab
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
tislelizumab
Primary: Phase 1a: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of BGB-26808, Phase 1a: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), Phase 1b: Overall Response Rate (ORR)
Secondary: Phase 1a and 1b: Disease Control Rate (DCR), Phase 1a and 1b: Duration of Response (DOR), Phase 1a: Apparent clearance (CL/F) for BGB-26808, Phase 1a: Area under the concentration-time curve (AUC) for BGB-26808, Phase 1a: Half-life (t1/2) for BGB-26808, Phase 1a: Maximum observed plasma concentration (Cmax) for BGB-26808, Phase 1a: ORR, Phase 1a: Time to maximum plasma concentration (Tmax) for BGB-26808
Oncology